Zyprexa and Task Engagement in Schizophrenia

Withdrawn before enrolling · Phase 3

Conditions studied: Schizophrenia, Schizoaffective Disorder

In brief

Individuals with schizophrenia frequently have impairments in attention. These impairments have been shown to be related to overall functioning. Some research suggests that Olanzapine may be associated with improvement in various aspects of attention. The primary purpose of this study is to determine whether switching from a typical antipsychotic to Olanzapine improves task engagement. Individuals who taking typical antipsychotics will be randomly assigned to either 1) remain on their typical antipsychotic medications, or 2) be switched from their typical antipsychotic medications to Olanzapine. All participants will be enrolled in a twice-weekly 20 session cognitive training program that is specifically designed to target attention deficits and promote active engagement. Improvements in attention will be compared between individuals who remained on their typical antipsychotic medications and those that were switched to Olanzapine.

Key facts

Study ID

NCT00440843

Run by

VA Connecticut Healthcare System

People needed

0

Starts

2007-02-01

Expected to finish

2012-06-01

Last updated by the study team

2013-12-23

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of schizophrenia or schizoaffective disorder
• Current medication regimen that includes any combination of first generation neuroleptics, for at least 30 days
• Referring psychiatrist agrees to transfer primary psychiatric care and medication prescription to the study doctor, for the duration of patient's participation in the study

You may not qualify if…

• Significant auditory/visual impairment that would interfere with study procedures
• Lack of aptitude in English that may interfere with the administration of the tests
• Current use of psychoactive substances that may affect attention (e.g. Amoxetine, Methylphenidate)
• Deviations from the prescription regimen not approved by study doctor
• Changes in the regimen of antipsychotics not included in the study's protocol
• Chart diagnosis of any other medical or neuropsychiatric illnesses known to impair brain function (e.g. mental retardation, traumatic brain injury, seizure disorder).
• Pregnant or breast-feeding females.
• Use of alcohol or drugs 4 weeks prior to beginning of study.
• For participants with history of substance dependence (excluding nicotine and caffeine) use of illicit substances (e.g. marijuana or crack) during study participation.
• Use of a depot antipsychotic within 4 weeks prior to baseline
• History or evidence of a medical or neurological condition that would expose the subject to an undue risk of a significant adverse event or interfere with study assessments
• Clinically significant abnormal laboratory test results at screening

Where it is running

• Columbia University Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.